[1]肖雪珍,袁东方,辛丹丹,等.Aglaroxin C对肝癌细胞体内外生长的抑制作用[J].新乡医学院学报,2018,35(9):761-765.[doi:10.7683/xxyxyxb.2018.09.003]
　XIAO Xue-zhen,YUAN Dong-fang,XIN Dan-dan,et al.Inhibiting effect of Aglaroxin C on growth of hepatocellular carcinoma in vitro and in vivo[J].Journal of Xinxiang Medical University,2018,35(9):761-765.[doi:10.7683/xxyxyxb.2018.09.003]
点击复制

Aglaroxin C对肝癌细胞体内外生长的抑制作用
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年9
页码:
761-765
栏目:
基础研究
出版日期:
2018-09-05

文章信息/Info

Title:
Inhibiting effect of Aglaroxin C on growth of hepatocellular carcinoma in vitro and in vivo
作者:
肖雪珍1; 2; 袁东方3; 辛丹丹1; 3; 齐　攀2; 冯跃庆2; 周　勇2; 岳爱民4; 杨留勤3; 王天翼5
(1.新乡医学院，河南　新乡　453003;2.新乡市中心医院头颈乳腺科，河南　新乡　453000；3.新乡市中心医院放疗科，河南　新乡　453000；4.新乡市中心医院普瘤二科，河南　新乡　453000；5.新乡市中心医院肿瘤科，河南　新乡　453000)
Author(s):
XIAO Xue-zhen1; 2; YUAN Dong-fang3; XIN Dan-dan1; 3; QI Pan2; FENG Yue-qing2; ZHOU Yong2; YUE Ai-min4; YANG Liu-qin3; WANG Tian-yi5
(1.Xinxiang Medical University,Xinxiang 453003,Henan Province,China;2.Department of Head and Neck Breast Surgery,the Central Hospital of Xinxiang City，Xinxiang 453000,Henan Province,China；3.Department of Radiotherapy,the Central Hospital of Xinxiang City,Xinxiang 453000,Henan Province,China;4.Department of General Oncology,the Central Hospital of Xinxiang City,Xinxiang 453000,Henan Province,China;5.Department of Oncology，the Central Hospital of Xinxiang City,Xinxiang 453000,Henan Province)
关键词:
Aglaroxin C; 肝癌细胞; 移植瘤小鼠; 抗肿瘤作用
Keywords:
Aglaroxin C; hepatocellular carcinoma cells; tumor-bearing mice; anti-tumor effect
分类号:
R735.7
DOI:
10.7683/xxyxyxb.2018.09.003
文献标志码:
A
摘要:
目的　探讨Aglaroxin C对人肝癌细胞HepG2体外增殖的影响，并初步探讨其对肝癌移植瘤小鼠的抗肿瘤作用。方法　体外培养人肝癌细胞HepG2，分别加入1、10、100 nmol·L-1及1、10、100 μmol·L-1Aglaroxin C作用24、48、72 h，采用细胞计数试剂盒(CCK-8)检测肝癌细胞HepG2的增殖抑制率，并计算Aglaroxin C的半数抑制浓度（IC50）。取25只Balb/c小鼠随机分为尾静脉对照组、尾静脉0.10 mg Aglaroxin C组、瘤内对照组、瘤内0.05 mg Aglaroxin C组、瘤内0.10 mg Aglaroxin C组，每组5只。各组小鼠左腋皮下接种鼠肝癌细胞H22建立肝癌移植瘤模型，模型建立成功后，尾静脉对照组、尾静脉0.10 mg Aglaroxin C组小鼠分别通过尾静脉注射生理盐水0.2 mL、0.50 g·L-1 Aglaroxin C 0.2 mL；瘤内对照组、瘤内0.05 mg Aglaroxin C组、瘤内0.10 mg Aglaroxin C组小鼠分别瘤内多点注射生理盐水0.2 mL、0.25 g·L-1 Aglaroxin C 0.2 mL、0.50 g·L-1 Aglaroxin C 0.2 mL；隔日1次，共4次。给药期间监测小鼠肿瘤体积变化；末次给药后24 h，剖取各组小鼠肿瘤组织，称质量并计算肿瘤抑制率；取肿瘤组织行苏木精-伊红染色，观察各组小鼠肿瘤组织病理学变化。结果　不同浓度Aglaroxin C干预人肝癌细胞HepG2 24、48、72 h后，同一时间点人肝癌细胞HepG2的增殖抑制率随Aglaroxin C浓度的增加而升高（P<0.05）；Aglaroxin C干预人肝癌细胞HepG2 24、48、72 h的IC50分别为73、25、82 nmol·L-1。给药干预2～8 d，尾静脉0.10 mg Aglaroxin C组小鼠肿瘤体积小于尾静脉对照组（P<0.05）；瘤内0.05 mg Aglaroxin C组、瘤内0.10 mg Aglaroxin C组小鼠肿瘤体积均小于瘤内对照组（P<0.05）；瘤内0.05 mg Aglaroxin C组小鼠肿瘤体积与尾静脉0.10 mg Aglaroxin C组比较差异无统计学意义（P>0.05），瘤内0.10 mg Aglaroxin C组小鼠肿瘤体积小于尾静脉0.10 mg Aglaroxin C组（P<0.05）。给药干预5～8 d，瘤内0.10 mg Aglaroxin C组小鼠肿瘤体积小于瘤内0.05 mg Aglaroxin C组（P<0.05）。尾静脉0.10 mg Aglaroxin C组小鼠肿瘤质量明显小于尾静脉对照组（P<0.05）；瘤内0.05 mg Aglaroxin C组小鼠肿瘤质量与尾静脉0.10 mg Aglaroxin C组比较差异无统计学意义（P>0.05），瘤内0.10 mg Aglaroxin C组小鼠肿瘤质量小于尾静脉0.10 mg Aglaroxin C组和瘤内0.05 mg Aglaroxin C组（P<0.05）。瘤内0.05 mg Aglaroxin C组小鼠肿瘤质量和肿瘤抑瘤率与尾静脉0.10 mg Aglaroxin C组比较差异无统计学意义（P>0.05）。瘤内0.10 mg Aglaroxin C组小鼠肿瘤抑瘤率高于尾静脉0.10 mg Aglaroxin C组和瘤内0.05 mg Aglaroxin C组（P<0.05）。显微镜下可见，瘤内0.10 mg Aglaroxin C组小鼠肿瘤组织坏死程度最明显。结论　Aglaroxin C可以显著抑制人肝癌细胞HepG2的体外增殖；对肝癌移植瘤小鼠具有显著的抗肿瘤活性。
Abstract:
Objective　To explore the inhibiting effect of Aglaroxin C on growth of hepatocellular carcinoma HepG2 in vitro and to evaluate its antitumor activity in tumor-bearing mice.Methods　The human hepatocellular carcinoma cell line HepG2 were cultured in vitro and the cells were intervened by 1，10，100 nmol·L-1 and 1,10,100 μmol·L-1Aglaroxin C for 24，48，72 h，respectively.The proliferation inhibition rate of human hepatocellular carcinoma cell line HepG2 was determined by cell counting kit-8 assay,and 50% inhibiting concentration of the Aglaroxin C was calculated.Twenty-five Balb/c mice were selected and randomly divided into tail vein control group,0.10 mg Aglaroxin C tail vein group，intratumoral administration control group,0.05 mg Aglaroxin C intratumoral administration group and 0.10 mg Aglaroxin C intratumoral administration group,with five mice in each group.Transplanted tumor model of hepatocellular carcinoma was established by subcutaneous inoculation of hepatocellular carcinoma cells H22 in left axilla of mice in each group.Subsequently,the mice in the tail vein control group and 0.10 mg Aglaroxin C tail vein group were injected 0.2 mL physiological saline through tail vein and 0.2 mL Aglaroxin C( 0.50 g·L-1),respectively.The mice in the intratumoral administration control group,0.05 mg Aglaroxin C intratumoral administration group and 0.10 mg Aglaroxin C intratumoral administration group were multipoint injected 0.2 mL physiological saline,0.2 mL Aglaroxin C (0.25 g·L-1) and 0.2 mL Aglaroxin C(0.50 g·L-1) into intratumor.Once every other day,four times in total.Changes of tumor volume in mice were measured during administration.Twenty-four hours after the last drug administration,tumor tissues of the mice in each group were also dissected out,the mass of tumor was measured，the tumor inhibition rate was calculated.Part of the tumor tissue was used to observe the pathological changes by hematoxylineosin staining.Results　At 24,48,72 h after treating the human hepatocellular carcinoma cell line HepG2 by Aglaroxin C with different concentration,the proliferation inhibition rate of human hepatocellular carcinoma cell line HepG2 increased with the increasing of Aglaroxin C concentration（P<0.05）,and the IC50 of the Aglaroxin C on the human hepatocellular carcinoma cell line HepG2 cells was 73,25,82 nmol·L-1.At 2-8 days of administration,the tumor volume of 0.10 mg Aglaroxin C tail vein group was smaller than that of the tail vein control group（P<0.05）;the tumor volume of 0.05 mg Aglaroxin C intratumoral administration group and 0.10 mg Aglaroxin C intratumoral administration group was smaller than that of the intratumoral administration control group（P<0.05）.There was no significant difference in the tumor volume between the 0.05 mg Aglaroxin C intratumoral administration group and 0.10 mg Aglaroxin C tail vein group (P>0.05);the tumor volume of 0.10 mg Aglaroxin C intratumoral administration group was smaller than that of 0.10 mg Aglaroxin C tail vein group（P<0.05）.At 5-8 days of administration,the tumor volume of 0.10 mg Aglaroxin C intratumoral administration group was smaller than that of 0.05 mg Aglaroxin C intratumoral administration group（P<0.05）.The tumor mass of 0.10 mg Aglaroxin C tail vein group was smaller than that of the tail vein control group（P<0.05）;the tumor mass of 0.05 mg and 0.10 mg Aglaroxin C intratumoral administration group was smaller than that of the intratumoral administration control group（P<0.05）;there was no significant difference in the tumor mass between the 0.05 mg Aglaroxin C intratumoral administration group and 0.10 mg Aglaroxin C tail vein group(P>0.05);the tumor mass of 0.10 mg Aglaroxin C intratumoral administration group was smaller than that of 0.05 mg Aglaroxin C intratumoral administration group and 0.10 mg Aglaroxin C tail vein group（P<0.05）.There was no significant difference in the tumor mass and inhibition rate between the 0.05 mg Aglaroxin C intratumoral administration group and 0.10 mg Aglaroxin C tail vein group (P>0.05).The tumor inhibition rate of 0.10 mg Aglaroxin C intratumoral administration group was higher than that of 0.10 mg Aglaroxin C tail vein group and 0.05 mg Aglaroxin C intratumoral administration group（P<0.05）.Under the microscope,the degree of tumor necrosis of the mice in 0.10 mg Aglaroxin C intratumoral administration group was the most obviously.Conclusion　Aglaroxin C treatment can significantly inhibit the proliferation of human hepatocellular carcinoma cell line HepG2 in vitro.It has the antineoplastic activity on the tumor-bearing mice.

参考文献/References:

［1］　KATSUTA E,TANAKA S,MOGUSHI K,et al.Age-related clinicopathologic and molecular features of patients receiving curative hepatectomy for hepatocellular carcinoma［J］.Am J Surg,2014,208(3):450-456.
［2］　LAFARO K J,DEMIRJIAN A N.Epidemiology of hepatocellular carcinoma［J］.Surg Oncol Clin N Am,2015,24(1):1-17.
［3］　SHEN Y,WEI Y,WANG Z,et al.TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization［J］.Cell Physiol Biochem，2015,35(4):1623-1632.
［4］　CHEN W,ZHENG R,ZHANG S,et al.Cancer incidence and mortality in China in 2013:an analysis based on urbanization level［J］.Chin J Cancer Res，2017,29(1):1-10.
［5］　RIMASSA L,ASSENAT E,PECK-RADOSAVLJEVIC M,et al.Tivantinib for second-line treatment of MET-high,advanced hepatocellular carcinoma (METIV-HCC):a final analysis of a phase 3,randomised,placebo-controlled study［J］.Lancet Oncol,2018,19(5):682-693.
［6］　KING M L,CHIANG C C,LING H C,et al.X-Ray crystal structure of rocaglamide,a novel antileulemic 1H-cyclopenta［b］benzofuran from Aglaia elliptifolia［J］.J Chem Soc Chem Commun，1982,20(20):1150-1151.
［7］　LEE S K,CUI B,MEHTA R R,et al.Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta（b）benzofuran lignans isolated from Aglaia elliptica［J］.Chem Biol Interact，1998,115(3):215-228.
［8］　ZHU Y,LAI X,ZHAO S,et al.Antitumor enhancement by irradiated haploidentical donor lymphocyte infusion of mice with melanoma［J］.Cell Physciol Biochem,2015,35(6):2181-2191.
［9］　YANG S,ZHANG B,GONG X,et al.In vivo biodistribution,biocompatibility,and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer［J］.Int J Nanomedicine,2016,11(default):2329-2343.
［10］　XIAO X,LIU Y,GUO M,et al.pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo［J］.J Biomate Appl,2016,31(1):23-35.
［11］　田怀平，高蕙敏，杨萍,等.华蟾素联合肝动脉化疗栓塞治疗原发性肝癌的疗效与安全性Meta分析［J］.世界中医药，2016，11（10）：2151-2155.
［12］　STONE S D,LAJKIEWICZ N J,WHITESELL L,et al.Biomimetic kinetic resolution:highly enantio- and diastereoselective transfer hydrogenation of aglain ketones to access flavagline natural products［J］.J Am Chem Soc,2015,137(1):525-530.

相似文献/References:

[1]郑颖娟,胡焕焕.不同来源的细胞因子诱导的杀伤细胞对肝癌细胞SMMC7721的杀伤效应比较[J].新乡医学院学报,,():000.
[2]卢　娜,李　超.蝎毒组分Ⅲ对原代培养的人肝癌细胞的抑制作用[J].新乡医学院学报,2003,20(01):011.
[3]卢 娜,李超.蝎毒组分Ⅲ对原代培养的人肝癌细胞的抑制作用[J].新乡医学院学报,2003,20(01):011.
[4]杨剑鑫,范丽玲,翁小易,等.肝星状细胞对肝癌裸鼠肝癌细胞上皮间质转化的影响[J].新乡医学院学报,2018,35(12):1048.[doi:10.7683/xxyxyxb.2018.12.002]
　YANG Jian-xin,FAN Li-ling,WENG Xiao-yi,et al.Effect of hepatic stellate cell on the epithelial-mesenchymal transition of hepatoma carcinoma cells in nude mouse[J].Journal of Xinxiang Medical University,2018,35(9):1048.[doi:10.7683/xxyxyxb.2018.12.002]
[5]黄琰菁,王　琳,李　赛,等.长链非编码RNA PCGEM1对肝癌Huh7细胞增殖、侵袭及凋亡的影响[J].新乡医学院学报,2019,36(5):406.[doi:10.7683/xxyxyxb.2019.05.002]
　HUANG Yan-jing,WANG Lin,LI Sai,et al.Effects of long noncoding RNA PCGEM1 on proliferation，invasion and apoptosis of hepatoma carcinoma Huh7 cells[J].Journal of Xinxiang Medical University,2019,36(9):406.[doi:10.7683/xxyxyxb.2019.05.002]

更新日期/Last Update: 2018-09-05